BeiGene, Ltd. (BGNE) Financials

BGNE Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 5.8 billion 2.2 billion
2023-09-30 5.5 billion 1.8 billion
2023-06-30 5.7 billion 1.9 billion
2023-03-31 6.0 billion 1.8 billion

BGNE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -388.5 million 92.9 million
2023-09-30 -260.4 million 96.0 million
2023-06-30 -415.4 million 103.4 million
2023-03-31 -689.4 million 75.3 million

BGNE Net Income

No data available :(

BGNE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 3.2 billion - 44.2 million
2023-09-30 3.2 billion - 48.7 million
2023-06-30 3.5 billion - 49.3 million
2023-03-31 3.8 billion - 57.1 million

BGNE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 104.1 million
2023-09-30 139.0 million
2023-06-30 104.6 million
2023-03-31 104.2 million

BGNE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 166.9 million 473.1 million 416.5 million -
2023-09-30 182.3 million 453.3 million 364.4 million -
2023-06-30 121.5 million 422.8 million 395.0 million -
2023-03-31 125.6 million 408.6 million 328.5 million -

BGNE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 634.4 million 128.5 million
2023-09-30 781.3 million 96.3 million
2023-06-30 595.3 million 518.8 million
2023-03-31 447.8 million 81.8 million

BGNE

Price: $153.58

52 week price:
129.52
270.57

Earnings Per Share: -8.45 USD

P/E Ratio: -16.01

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 346500

Ebitda: 116.2 million

Market Capitalization: 15.1 billion

Links: